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Abstract

When a cancer patient develops a new tumor it is necessary to determine if this is
a recurrence (metastasis) of the original cancer, or an entirely new occurrence of
the disease. This is accomplished by assessing the histo-pathology of the lesions,
and it is frequently relatively straightforward. However, there are many clinical
scenarios in which this pathological diagnosis is difficult. Since each tumor is
characterized by a genetic fingerprint of somatic mutations, a more definitive diagnosis is possible in principle in these difficult clinical scenarios by comparing
the fingerprints. In this article we develop and evaluate a statistical strategy for
this comparison when the data are derived from array comparative genomic hybridization, a technique designed to identify all of the somatic allelic gains and
losses across the genome. Our method involves several stages. First a segmentation algorithm is used to estimate the regions of allelic gain and loss. Then the
broad correlation in these patterns between the two tumors is assessed, leading
to an initial likelihood ratio for the two diagnoses. This is then further refined
by comparing in detail each plausibly clonal mutation within individual chromosome arms, and the results are aggregated to determine a final likelihood ratio.
The method is employed to diagnose patients from several clinical scenarios, and
the results show that in many cases a strong clonal signal emerges, occasionally
contradicting the clinical diagnosis. The “quality” of the arrays can be summarized by a parameter that characterizes the clarity with which allelic changes are
detected. Sensitivity analyses show that most of the diagnoses are robust when
the data are of high quality.
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Abstract
When a cancer patient develops a new tumor it is necessary to determine if this is a
recurrence (metastasis) of the original cancer, or an entirely new occurrence of the
disease. This is accomplished by assessing the histo-pathology of the lesions, and it is
frequently relatively straightforward. However, there are many clinical scenarios in which
this pathological diagnosis is difficult. Since each tumor is characterized by a genetic
fingerprint of somatic mutations, a more definitive diagnosis is possible in principle in
these difficult clinical scenarios by comparing the fingerprints. In this article we develop
and evaluate a statistical strategy for this comparison when the data are derived from
array comparative genomic hybridization, a technique designed to identify all of the
somatic allelic gains and losses across the genome. Our method involves several
stages. First a segmentation algorithm is used to estimate the regions of allelic gain and
loss. Then the broad correlation in these patterns between the two tumors is assessed,
leading to an initial likelihood ratio for the two diagnoses. This is then further refined by
comparing in detail each plausibly clonal mutation within individual chromosome arms,
and the results are aggregated to determine a final likelihood ratio. The method is
employed to diagnose patients from several clinical scenarios, and the results show that
in many cases a strong clonal signal emerges, occasionally contradicting the clinical
diagnosis. The “quality” of the arrays can be summarized by a parameter that
characterizes the clarity with which allelic changes are detected. Sensitivity analyses
show that most of the diagnoses are robust when the data are of high quality.

KEY WORDS: Statistical diagnosis; Likelihood ratio; Array CGH; Second primary
cancer; Cancer metastasis.

1
http://biostats.bepress.com/mskccbiostat/paper15

1. Introduction

The defining feature of cancer is metastasis, the ability of tumors to colonize distant sites
of the body. Independent (second primary) cancers also occur frequently.
Distinguishing a second primary from a metastasis is often of great clinical relevance, as
it can affect the appropriateness of local (surgical) versus systemic (medical) treatment.
Historically pathologists have distinguished these on the basis of gross and microscopic
pathologic criteria. However, in recent years cancer investigators have begun to explore
new methods to accomplish this by comparing the molecular profiles of the two tumors.
These studies involve the side-by-side comparison of pairs of tumors (from the same
patient) on the basis of patterns of somatic mutations, such as allelic gains or losses,
micro-satellite instability, or point mutations in genes that frequently experience somatic
mutations in tumors. In this article we explore how to construct a formal statistical
comparison of the mutational patterns in the setting in which the two tumors have been
evaluated using genome-wide array comparative genetic hybridization (ACGH), a
molecular genetic technique designed to identify allelic gains and losses across the
entire genome of a tumor.

These studies have potentially important clinical implications. For example, a patient
treated effectively for a localized primary head and neck cancer may at a later date
present with a solitary lung nodule. If the nodule is a localized second primary lung
cancer it can be treated effectively by surgery, though lung surgery is risky and very
invasive. On the other hand, if the tumor is a metastasis from the head/neck primary, the
prognosis of the patient is necessarily poor, as the cancer will almost certainly have also
metastasized to other parts of the body (even though these other metastases may not
yet be detectable). In this case invasive surgery would impose needless risks and
morbidity on a patient who will have relatively little time left to live. Yet if the two tumors
have the same cell type the pathologist has essentially no direct evidence on which to
base the diagnosis.

In making this differential diagnosis our fundamental purpose is to determine whether or
not the tumors share a clonal origin. That is, one wishes to determine if both tumors are
derived from a single “clonal” cell that experienced the pivotal mutations that led to tumor
development. Many studies exploring the use of molecular profiling in this context have
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been conducted in recent years. For example, investigators studying lung cancer have
used microsatellite markers to distinguish patterns of microsatellite instability (Huang
2001, Dacic 2005, Geurts 2005, Leong 1998, Shin 2001) and several investigators have
also used mutational analysis of the important cancer genes p53 and/or K-ras
(Hiroshima 1998, Holst 1998, Lau 1997, Shimizu 2000, Shin 2001, Murase 2003,
Matsuzoe 1999, Sozzi 1995, van Rens 2002). Similar studies have been conducted to
distinguish contralateral breast cancers from metastases, and in other cancer sites
(Imyanitov 2002, Regitnig 2004, Kollias 2000, Janschek 2001, Tse 2003, Schlechter
2004, Stenmark-Askmalm 2001, Chunder 2004). By studying the mutational pattern, one
can establish a genetic fingerprint of the tumor. When the mutational profiles of two
apparently independent primary tumors from the same patient are compared, it is
possible in principle to see whether these genetic fingerprints are sufficiently similar that
we can determine with confidence that they share a clonal origin, i.e. the second primary
is really a metastasis from the first primary.

The comparison of mutational profiles of tumors to determine clonality is a challenging
statistical problem, and a number of authors have proposed techniques for this purpose.
In earlier work we examined two new statistical tests, based on the setting in which the
mutational events at candidate genetic loci are assessed for correlation, with a view to
determining if the correlation exceeds the level that is plausible on the basis of chance
(Begg et al. 2007, Ostrovnaya et al. 2008). These tests have been shown to be
reasonably powerful provided that information is available from a considerable number
of candidate genetic loci that experience mutational events with reasonably high
frequency in the cancer under study, and that the “signal” is relatively strong, i.e. the
preponderance of the observed somatic mutations occur in the clonal phase of
development. Other authors have approached this problem in different ways. For
example Sieben et al. (2003) and Brinkmann et al. (2004) both construct likelihood ratios
to distinguish the evidence favoring the two hypotheses, though the construction is
somewhat different in each case. Another approach was advocated in earlier work by
Kuukasjarvi et al. (1997), who proposed a measure of clonal relatedness based on the
frequency of occurrence of concordant mutations in the tumors, and this measure has
been used by other authors such as Jiang et al. (2005) and Goldstein et al. (2005a,b).
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The preceding methods are all based on the setting in which we observe mutations in a
pre-specified set of candidate markers in each tumor, and we evaluate the collective
concordance of these mutational profiles. However, there are a limited number of
genetic loci at which mutations are known to occur frequently in tumors, and these tend
to differ between cancer sites. As a result, sometimes very few mutations are observed
in a specific patient, even when a relatively comprehensive set of loci have been
examined, and so there can be limited statistical power to distinguish the two diagnoses
reliably (Orlow et al. 2008). Since the common somatic mutations in tumors are
frequently losses or gains of segments of DNA, the issue of clonality can be studied for
the entire genome using array technology, specifically array comparative genomic
hybridization (ACGH) (Pinkel et al. 1998). By scanning the entire genome for copy
number changes this technology has the potential to provide a comprehensive
comparison of the two mutational profiles, and to provide insights beyond those available
from studies using a pre-defined set of candidate markers. In particular, ACGH can
pinpoint the places in the genome where these gains and losses begin and end, offering
the potential for identifying the exact matches that are the hallmark of clonal mutations.

Statistical methods for comparing ACGH data in this context have typically employed
strategies that simply count mutational events, as in the methods described above for
studies based on markers at candidate genetic loci. For example, investigators have
used data from the arrays to define the presence or absence of, say, loss of
heterozygosity (LOH) at the level of the chromosome arm (Jiang et al. 2005) or
chromosome band (Teixeira et al. 2004) in order to define the unit of analysis for
statistical tests or clustering algorithms. Many investigators have evaluated the similarity
between profiles only visually and through listing the chromosomes arms or bands that
have similar and different alterations, for example Nishizaki (1997), Weiss (2003), Wa et
al. (2005), Knosel (2005), Ruiz (2007) , Park (2007), Nestler (2007), Haller (2007) and
Agaimy (2007). More specific approaches have been used by Waldman et al. (2000)
who employed three distinct strategies for classifying pairs of tumors as clonal or
independent. First, these investigators used hierarchical clustering of the marker values
on the array, designating tumors as clonal if they cluster together in a pair. Hierarchical
clustering has also been used by Ghazani et al (2007), Teixeira et al. (2004) and
Agelopoulos (2003). Another strategy considered by Waldman et al. is to simply report
the percentage of chromosome arms with concordant gains or losses. Finally, this group
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has used a similarity score that characterizes the broad correlation of gains and losses
across chromosome arms. The similarity score is then benchmarked against the
distribution of this measure when tumors from different patients are compared. Some of
these strategies were further used in Hwang (2004) and Nyante (2004), published by the
same group, and Torres (2007).

None of these methods have taken advantage of the distinctive evidence available from
ACGH data when compared with studies involving candidate genetic loci, namely the
granularity of the information regarding the allelic gains and losses. In principle, this
feature of the data provides the ability to pinpoint the start and stop regions of the allelic
changes, with a view to determining an exact match between the mutations on the two
tumors. An exception is the recent article by Bollet et al. (2008) where a modified version
of the similarity score proposed by Waldman et al. (2000) was used to reflect the relative
frequency of exact matches of estimated end points of detected allelic changes. In our
experience the noise level in the arrays is usually too great to identify the exact
endpoints of the allelic changes with confidence, and so matching algorithms need to
address directly the statistical variation in the estimation of where allelic changes have
occurred, and the positioning of the endpoints of the gain or loss. Furthermore, a
comprehensive approach for making the diagnosis of the second tumor as clonal versus
independent (of the first tumor) needs to take into account the broad correlation of the
observed allelic gains and losses on the two tumors, as well as interrogating specific
matching gains and losses to determine the probabilities that these matches represent
clonal somatic events. In this article we outline a comprehensive statistical diagnostic
strategy constructed along these lines, explore its performance on several available
datasets, and describe a research agenda that will be needed to validate its statistical
properties.

2. Examples

We utilize data from various sources to illustrate the challenges faced. These include
two unpublished studies in which we are involved as co-investigators, and two studies
from the literature for which the data are publicly available.
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We introduce the problem in the context of an example in which the evidence favoring
the clonal origin of the pair of tumors is quite strong. This involves two squamous cell
tumors from a patient with cancer of the mouth. These were suspected of being related
tumors by the pathologist, and indeed the molecular profiles support this diagnosis. The
two tumors have been analyzed using a BAC array (Pinkel et al. 1998; Snijders et al.
2001), and the results are displayed in Figure 1. Each dot on the graph is a marker value
that represents the allelic copy number at a specific genetic locus (there are
approximately 2400 such markers on a BAC array). The markers are displayed
sequentially across the 22 chromosomes, with the two tumors aligned vertically.
Chromosomes X and Y are excluded. The horizontal black lines represent the normal
copy number (i.e. the expected 2 copies). If the markers in a region are significantly
higher than the black line then we conclude that there has been an allelic gain, and
these are represented by red lines. Allelic losses (below the line) are represented by
blue lines. The locations of gains and losses are determined by a statistical
“segmentation” algorithm. Many statistical techniques for ACGH segmentation are
available. We have used the circular binary segmentation (CBS) algorithm (Olshen et al.
2004), a method that has been shown to have good statistical properties (see Lai et al.
2005; Willenbrook and Fridyland 2005). For Figure 1, and throughout this manuscript,
we have used a one-step CBS algorithm that picks the most prominent allelic change
within a chromosome arm but does not search for more complex patterns of gains
and/or losses (see later discussion). We used a significance level of 0.01, and further
considered a significant segment to be a true allelic change only if the mean marker
value in the segmented band exceeded a distance of 1.25 median absolute deviations
(1.25 MAD criterion) from the normal copy number benchmark. This further criterion is
intended to eliminate experimental artifacts such as batch effects. Note that the
thresholds for gain or loss are different for every array and depend on the noise level.

The plots in Figure 1 show a broad correlation between the patterns of allelic changes.
For example there appears to be a loss of the entire chromosome arm on 3p on both
tumors. Other concordant whole arm changes are observed for 8q(gain),
16q(gain),19p(gain) and 20p(gain). In general, the losses and gains appear to be fairly
strongly correlated. That is there seem to be more concordances than we might expect
by chance. However, the real strength of the evidence favoring the clonal origin of these
tumors lies in the precision of the matching of allelic changes that occur within
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chromosome arms. For example there is a common loss on 10q, and a magnified
display of the results for this chromosome arm is provided in Figure 2. Here we see
strong evidence of a region of loss in the middle of the arm that looks similar in both
tumors. If this allelic loss is indeed “clonal”, then the true change must begin and end at
exactly the same genetic locations. However, the noise in the marker values, and the
resulting uncertainty surrounding the estimation of the region of loss, can lead to
statistical error in the estimated regions of loss. For 10q the regions of loss are closely
but not exactly matched. Nonetheless, this does appear, visually, to be a plausible clonal
event. Our challenge in this article is to assess the strength of evidence for and against
the hypothesis that this event is indeed clonal. We then need to aggregate this evidence
with the evidence from all of the other chromosome arms in order to obtain a diagnosis
for the two tumors. We note that this patient is from a study of 21 head and neck tumors
from 9 patients conducted at the University of California, San Francisco by one of us
(DGA), and we will present an analysis of this patient and a summary of the analyses for
all tumor combinations later in Section 5.

Typically, the evidence for or against clonality is much less clear-cut than for this patient.
Our second example involves two skin melanomas that have been diagnosed in the
same patient. These melanomas were classified as independent primaries by the
pathologist, and they occurred 2.4 years apart in distinct anatomic locations, one on an
arm and the other on a leg. This time the arrays are from the 244K Agilent platform, an
array with far more marker values than the BAC arrays featured in the first example.
However, the data for this patient are quite noisy, and so we elected to perform our
analyses using new marker values that represent averages of 49 adjacent markers. This
averaging was accomplished to reduce the degree of scatter. It also leads to a total
number of markers that is of the same order of magnitude as for the BAC arrays. This
patient’s data are plotted in Figure 3. For these two tumors there are some notable
similarities. Indeed the patterns in the higher numbered chromosomes are visually
similar, and there is a moderately strong overall correlation across the genome,
suggesting that the clinico-pathological diagnosis that the two melanomas are
independent may be wrong. However, comparison of concordant within-arm allelic
changes reveals only one change that strongly favors a clonal origin (on 2p) while most
of the other observed changes appear to represent independent somatic events. This
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patient is from a study of clonality in 19 patients with double primary melanomas (Orlow
et al. 2008).

We also analyze in detail publically-available datasets from two published studies. In the
first study (Bollet et al. 2008) the investigators have examined pairs of breast cancers
that occurred separately within the same (ipsilateral) breast in 22 patients. Some of
these tumor pairs are suspected to be independently occurring breast cancers on the
basis of clinico-pathologic information, while in other cases the second tumors are
suspected to be metastases. The ACGH data were obtained from the Affymetrix
Genechips Human Mapping 50K Array and are available through ACTuDB (Hupe et al.
2007). In order to magnify the signal and diminish the array artefacts we are using these
data averaged over 15 adjacent markers in our analysis. Again this leads to a total
number of markers of a similar order of magnitude as the other datasets. In a second
study, also involving breast cancer, Hwang et al. (2004) have studied the tumors from
women with an invasive lobular carcinoma (ILC) who had previously been diagnosed
with lobular carcinoma in situ (LCIS). Here the investigators were interested in the
scientific issue of whether LCIS is a precursor lesion for invasive breast cancer. This
dataset involves 24 pairs of tumors, and the tumors were analyzed using BAC arrays
with a total of approximately 2400 markers.

3. Conceptual Model

Our analytic goal is conceptually straightforward. We wish to determine whether the two
tumors are biologically independent, or whether the tumors are clonally related, i.e. both
originating from the same “clonal” cell in which the acquired pivotal mutations occurred
that provoked the cell to proliferate uncontrollably, leading ultimately to cancer. Thus, in
our hypothesis of independent origin of the tumors, the sets of somatic mutations on
each tumor must have occurred independently of each other. Under the clonal
hypothesis the two tumors must possess one or more mutations that are identical. The
existence of these clonal mutations ensures that a positive correlation in the mutational
profiles would be expected, and so examination of the strength of this correlation is a
major aspect of our analysis. However, we note that correlation of the patterns of gains
and losses is likely even in independent tumors. This is because allelic gains and losses
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tend to be observed in tumors in genetic regions for which there is a selective
advantage, such as in the neighborhood of oncogenes or tumor suppressor genes.
Thus, even in the absence of clonal origin of the tumors, there will be a common
tendency for gains and losses to occur on the same chromosome arms. Our methods
adjust for this phenomenon using background data to estimate the probabilities of gains
and losses for each chromosome arm for the cancer type under investigation. Also, in
clonal tumors, we expect additional “independent” allelic changes in each cell colony to
occur, thereby adding “noise” to the clonal signal. Statistical noise in the marker values
can also be accentuated for various experimental reasons: the tumor sample may be
contaminated with an unknown proportion of normal cells; the tumor itself may have
developed considerable heterogeneity of cell clones with distinct somatic changes; there
may be artefacts in the array technology; there may be copy number variants in the
germ line that masquerade as clonal events.

After examining the broad pattern of correlation across the genome, we examine more
carefully the specific chromosome arms on which concordant mutations have been
observed, i.e. a loss on both tumors or a gain on both tumors. We examine the exact
locations of these allelic gains or losses to determine the plausibility that the two
changes are actually clonal, i.e. they represent the same change that occurred in the
original clonal cell. We have developed new methodology for accomplishing this
comparison. Our overall strategy is based on the premise that these precise withinchromosome comparisons provide the most compelling evidence for identifying clonal
tumors.

We approach the problem from a “theoretical” perspective. That is, we construct a
sampling model that we conjecture to be a realistic representation of the way in which
the marker data are generated under the two competing diagnoses (independent origin
of the tumors versus clonal origin). This model is then used to obtain statistical results
that characterize the relative strength of the evidence favoring each of these
hypotheses. The results are expressed as likelihood ratio statistics. Ultimately, a more
satisfying (and better calibrated) strategy may be to generate an optimal discrimination
measure, and then characterize the distribution of the measure in training data
consisting of tumor pairs “known” to be clonal and pairs known to be independent, all
derived from the relevant clinical scenario under investigation, e.g. cancers of a specific

9
http://biostats.bepress.com/mskccbiostat/paper15

anatomic site and/or cell type. However, at present there are very few data of this nature
available, and indeed one cannot be sure that diagnoses based on classical pathology
are correct. That is, our problem is akin to the creation and evaluation of a diagnostic
test when there is no “gold standard” reference test (Begg 1987). Despite this problem
our diagnostic setting is unusual in that we can construct plausible reference
distributions for our diagnostic test statistics under the “independence” hypothesis. We
can do this by pairing tumors from different patients. By definition, all such pairs of
tumors must have occurred independently. We use this strategy to calibrate our results
for each dataset.

4. Detailed Analytic Model

The initial step of the analysis is a segmentation analysis of each of the chromosome
arms of the two tumors (see Figures 1 and 3). In our analyses we have used the CBS
algorithm with the significance level and further constraint as defined in the previous
section. This analysis allows us, for each chromosome arm of each tumor, to assign the
arm as representing an allelic gain, a loss, or no change. Comparing the patterns from
the two tumors, we identify arms in which gains occur in both tumors or losses occur in
both tumors. We define the former as “concordant gains”, and the set of such arms is
represented by Ψg . Likewise the set of arms with concordant losses is denoted Ψl .

Correlation of Mutational Patterns

The arrays we have been using contain sufficient data for 39 autosomal chromosome
arms that are considered to be statistically independent units of the genome. Let rggi = 1
if gains are observed on the ith chromosome arm on both tumors (0 otherwise), rlli = 1 if
losses are observed on both tumors, rgli = 1 if there is a gain on one tumor and a loss on
the other, rgni = 1 if there is a gain on one tumor and no change on the other, rln i = 1 if
there is a loss on one tumor and no change on the other, and rnni = 1 if there is no
change on either tumor. In evaluating the correlation in these outcomes between the
tumors we must recognize the fact that the probabilities of gains and losses will be
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specific to each chromosome arm, in addition to being specific to the tumor type under
investigation. For the ith chromosome arm let these probabilities be p gi for a gain, p li for
a loss, and p ni for no change, with p gi + p li + p ni = 1 . Our analytic strategy requires
knowledge of these marginal probabilities, and there are growing data resources for this
purpose. However, in our analyses we have calculated the empirical relative frequencies
of gains and losses in each dataset using the cohort of pairs of tumors being analyzed,
and have used these as estimates of p *gi , pli* , and p ni* . We then obtained patientspecific estimates of the marginal probabilities using

log it ( p gi ) = log it ( p *gi ) log it[(2rgg + rgl + rgn ) / 78] / ∑ log it ( p *gi ) / 39, and analogous
formulas for p li and p ni , where rgg =

∑r

ggi

, etc. We have used these rescaled

i

probabilities to avoid the risk of creating extreme results merely because the overall
mutation frequency is unusually low or high for the patient, since this overall frequency is
in part determined by the “quality” of the array data (see Sections 5 and 6).

For our problem of differential diagnosis we have chosen to evaluate the evidence
distinguishing the two diagnoses ( H I , the independence hypothesis, and H C , the
clonal hypothesis) using likelihood ratios. As our knowledge develops, it should be
possible to refine the diagnostic strategy to accommodate the prior probabilities for each
diagnosis, based on the long-term relative frequencies of the two diagnoses in the
clinical scenario, adjusted also possibly using relevant clinical information, such as the
concordance of cell type and other features that inform current pathologic diagnostic
rules.

We construct a likelihood as follows:

r
rlli
⎡
(1 − c) 2 pgi2 ⎤ ggi ⎡
(1 − c) 2 pli2 ⎤
P (r | c) = ∏ ⎢cpgi +
⎥ ⎢cpli +
⎥
1 − cpgi − cpli ⎦⎥ ⎣⎢
1 − cpgi − cpli ⎦⎥
i ⎣
⎢
r
r
r
r
⎡ 2(1 − c) 2 p gi pli ⎤ gli ⎡ 2(1 − c) pgi pni ⎤ gni ⎡ 2(1 − c) pli pni ⎤ ln i ⎡
⎤ nni
pni2
⎢
⎥ ⎢
⎥ ⎢
⎥ ⎢
⎥
⎣⎢ 1 − cpgi − cpli ⎦⎥ ⎣⎢ 1 − cpgi − cpli ⎦⎥ ⎣⎢1 − cpgi − cpli ⎦⎥ ⎣⎢1 − cpgi − cpli ⎦⎥

(1)

where r = {rggi , rlli , rgli , rgni , rln i , rnni } represents the pattern of gains and losses across all
of the chromosome arms. The parameter c represents, in clonal pairs of tumors, the
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proportion of observed mutations that are expected to be clonal, and we assume that
this proportion applies to both gains and losses equally. By specifying a value for c we
can obtain the likelihood ratio for the clonal versus the independence diagnoses using

P (r | c) / P(r | c = 0) .
Comparisons of Specific Concordant Mutations

We augment the broad evaluation of correlation across the genome with specific
comparisons for chromosome arms on which a common overlapping loss or gain
spanning only a part of a chromosome has been observed on both tumors. The goal is
to assess the evidence for and against the clonal origin of each specific mutational
change. Let xuk represent the measurement of the u th marker of the k th tumor on a
specific chromosome arm which has concordant allelic changes on the two tumors,
where u = 1,.., n, and k = 1,2, and where n represents the number of markers on the
chromosome arm. Let the copy number change begin at marker ik and end at marker

j k for the k th tumor. That is, markers ik through j k , inclusive, represent the markers of
allelic gain (or loss). If the mutation under investigation is clonal then i1 = i2 and j1 = j 2 .

The CBS algorithm is used to obtain estimates of the endpoints, denoted iˆk
and ĵ k . We define a “closeness” statistic t , representing the similarity of the length and
positioning of the two changes:

t = iˆ1 − iˆ2 + ˆj1 − ˆj 2 .

(2)

Thus small values of t are indicative of a possible clonal mutation. Under H I we assume
that the allelic changes have arisen independently, and so the reference distribution for t
under H I should thus reflect the distribution of t when independent allelic gains or losses
have been generated on each tumor. To generate an appropriate reference distribution
we must recognize that while chromosomal breakpoints may occur randomly in cells, the
alteration is more likely to be retained if it contains a gene or genes for which there is an
advantage to having an abnormal number of copies, such as an oncogene or a tumor
suppressor gene. To address this phenomenon we first generate a location for a
hypothetical mutational hotspot, which we presume to be located where the observed
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regions of allelic loss or gain on the two tumors overlap. We then randomly generate
new (true) regions of allelic change for the two tumors, restricted to the set of changes
that overlap the hotspot. We permute the data (as described below) and use the CBS
algorithm on the permuted data for each tumor to estimate the start and stop points for
the allelic changes. If concordant allelic changes are detected by CBS on both tumors
then the data set is considered to be “admissible”, and the estimated endpoints are used
to calculate the reference test statistic. Re-applying the same segmentation algorithm
(CBS) to the data simulated in the reference distribution automatically adjusts the
procedure for the segmentation error. This process is then repeated a large number of
times to establish the reference distribution for t under H I .

Let the sample means of the segmented marker values be

μ̂ k = ∑ xuk /( ˆj k − iˆk + 1) for the mutated portion and
u =iˆk

n
⎡ iˆk −1
⎤
ˆ
θ k = ⎢∑ xuk + ∑ xuk ⎥ /(n − ˆj k + iˆk − 1) for the normal copy number portion. These are
u = ˆj k +1
⎣ u =1
⎦

used to obtain residuals for each of the marker values:-

ruk = xuk − θˆk for u < iˆk or u > ˆj k
= xuk − μ̂ k for iˆk ≤ u ≤ ˆj k .
The reference distribution is constructed using the following steps. [An asterisk denotes
terms representing the reference distribution.]
(1) Generate the location of the mutational hotspot h * , where h * is selected
uniformly from the common interval, i.e. the interval between max (iˆ1 , iˆ2 ) and min

( ˆj1 , ˆj 2 ). If the intervals do not overlap, separate hotspots are generated for each
tumor. [For simplicity we assume that the hotspot occurs at a marker value, and
define U (i, j ) to represent uniform sampling of the markers between i and j ,
inclusive.]
(2) Generate the “true” endpoints of the allelic changes in the reference sample:

i1* and i2* sampled from U(1, h * ) and j1* and j 2* sampled from U( h * ,n).
(3) Obtain {ruk* }, a permuted set of the residuals {ruk }, permuted separately for each
tumor.
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*
(4) Create the permuted marker values {xuk
} using
*
xuk
= θˆ + ruk* if u < ik* or u > j k*

= μˆ + ruk* if ik* ≤ u ≤ j k* ,
where

(n − ˆj1 + iˆ1 − 1)θˆ1 + (n − ˆj 2 + iˆ2 − 1)θˆ2
(n − ˆj1 + iˆ1 − 1) + (n − ˆj 2 + iˆ2 − 1)
( ˆj − iˆ + 1) μˆ 1 + ( ˆj 2 − iˆ2 + 1) μˆ 2
μˆ = 1 1
.
( ˆj1 − iˆ1 + 1) + ( ˆj 2 − iˆ2 + 1)

θˆ =

(5) Segment the new datasets to obtain the estimated endpoints of the regions of
allelic change, denoted (iˆ1* , ˆj1* ) and (iˆ2* , ˆj 2* ). Include the results only if these
changes are both determined to be significant by the CBS segmentation method.
(6) Calculate the reference value for the test statistic using

t * = iˆ1* − iˆ2* + ˆj1* − ˆj 2* .
(7) Repeat the process a large number of times to obtain the distribution of t * .

A reference distribution for t under the clonal hypothesis H C can be generated in
exactly the same manner, merely by changing step 2. Here we randomly generated the
endpoints of the allelic change below and above the hotspot, i * from U(1, h ), and

j * from U( h, n ), and set i1* = i2* = i * and j1* = j 2* = j.* Also, in step 2, if the intervals do
not overlap, a single hotspot is generated between the two intervals.

Smoothed estimates of these two reference distributions (densities), denoted f I (t ) and

f C (t ) , are then obtained using kernel density estimation, with a standard default R
bandwidth selection and kernel (Sheather and Jones 1991). The ratio f C (t ) / f I (t ) is
then used as the likelihood ratio to characterize the evidence for and against the
hypothesis that the mutation under investigation is clonal.

In an effort to assess the validity of this strategy from a purely statistical perspective we
have evaluated its frequentist properties by performing simulations in which the
reference distribution of t is evaluated under a model in which the two mutations are

14
Hosted by The Berkeley Electronic Press

generated independently, and the noise in the marker values is generated by a normal
distribution. Specifically, we determined the mean value for markers at normal copy
number, denoted by θ , and the mean in the region of allelic change, denoted by μ , with
common variance σ 2 . These were chosen to specify the signal strength, represented by

μ − θ / σ , and one of the means was set to 0 and the variance set to 1 without loss of
generality. For each simulation we first selected a true mutational hotspot at marker h .
This was randomly generated from the n markers for each data set. We then generated
a data set as follows. First the “true” endpoints of the allelic changes were randomly
generated, i1 and i2 as U(1, h ), and j1 and j 2 as U( h, n ). Observed marker values were
generated as normal random variables. That is, xuk was generated as N( θ , σ 2 ) for u < ik
or u > j k and as N( μ , σ 2 ) for ik < u < j k The CBS algorithm was used on these data to
estimate the endpoints, denoted iˆ1 , ˆj1 , iˆ2 , ˆj 2 , and the test statistic t was calculated using
(2).

Following the procedure outlined above, the tail area probability (p-value) was calculated
as the relative number of times that t* ≤ t based on 1000 replicates from the reference
distribution. The entire process was then repeated 1000 times to determine the relative
frequency matching the tail-area probabilities generated by the algorithm. The simulation
standard error is about ± 0.02. The procedure was allowed as many attempts as
necessary to complete the 1000 replicates required, and likewise it was allowed as many
attempts as necessary to generate a significant, concordant data set. In configurations
with a signal strength ranging from 0.5 standard deviation units to 3, and numbers of
markers from 65 to 140 (the typical numbers of markers on a chromosome arm of the
arrays used in some of our examples, after data averaging) the observed relative
frequencies from the simulation ranged from 0.02 to 0.06 for tail-area probabilities less
than 0.05 as determined by our permutation-based algorithm. This exercise gives us
confidence that our permutation-based procedure produces tail-area probabilities that
are approximately accurate when data are generated using normal errors in the marker
values.

Global Analysis and Patient Diagnosis
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The final step in the analysis is the aggregation of the evidence obtained from the
correlation of the broad mutational patterns and the similarity analyses of specific
concordant mutations. This provides a final assessment of the strength of the evidence
favoring H I versus H C for the two tumors. We create an augmented likelihood that
combines the evidence from these two sources. To do this we need to recognize that
even for clonal tumors not all observed mutations are expected to be clonal. However,
since our likelihood only involves comparison of potentially clonal concordant mutations,
we need a mixing parameter that represents, under the clonal hypothesis, the proportion
of “concordant” mutations that are expected to be clonal (as opposed to the proportion of
all observed mutations that are clonal, denoted by the parameter c ). Setting

bgi =

cpgi
(1 − c) 2 pgi2
cpgi +
1 − cpgi − cpli

bli =

cpli
(1 − c) 2 pli2
cpli +
1 − cpgi − cpli

and

the full likelihoods under the two hypotheses can be expressed as follows:

LI = ∏ P(r | c = 0)∏ f Ii (t i )∏ f Ii (t i )
iεΨg
iεΨl
i
LC = ∏ P(r | c)∏ (bgi f Ci (ti ) + (1 − bgi ) f Ii (ti ))∏ (bli f Ci (ti ) + (1 − bli ) f Ii (ti )) ,
iεΨ g
iεΨl
i

(3)

where f Ii (ti ) and f Ci (t i ) represent the reference distributions of the similarity statistic t i
for the comparison on the i th chromosome arm.

Ultimately the differential diagnosis for the patient under investigation depends
on the prior probabilities of these two diagnoses, reflecting the long-run relative
frequencies with which pairs of tumors in the given clinical setting are clonal or
independent, augmented if necessary with other relevant information extraneous to the
mutational profiles. If the prior probability that the tumors are clonal is defined to be π ,
and the corresponding posterior probability is Π , then the posterior odds is given by

L
Π
π
=
• C.
1 − Π 1 − π LI
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However, in the absence of meaningful prior information in our present state of
knowledge, we focus on likelihood ratios throughout, effectively assuming that π = 0.5.

5. Data Analyses

We analyze initially the illustrative cases that were described earlier in Section 2. Data
from the first of these, involving two squamous cell tumors from a patient with cancer of
the mouth are presented in Figures 1 and 2. The segmentation analysis reveals 8 allelic
gains in tumor 1 and 7 allelic gains in tumor 2, with 4 of these occurring on the same arm
(concordant gains). There are 8 losses on tumor 1 and 11 losses on tumor 2, and 7 of
these are concordant losses. The resulting likelihood ratio statistic using (1) is 214 to 1 in
favor of clonality versus independence. In other words, the degree of broad correlation in
allelic gains and losses is quite strongly supportive of the clonal hypothesis. Of the 11
chromosome arms with concordant changes, several involve a whole arm gain or loss in
at least one of the tumors. Thus there are 6 arms remaining for which we can conduct
the detailed comparison of the endpoints of the changes. One of these comparisons
(10q) is plotted on Figure 2. The odds for this loss favor the clonal hypothesis by a factor
of 3 to1. Of the 5 remaining comparisons three favor the clonal hypothesis: 8q, 79 to 1;
11q, 120 to 1; 18p, 34 to 1. The remaining two comparisons appear to represent
independent mutations: 5q, 6 to 1 in favor of independence; 13q, 5 to 1 in favor of
independence. When these comparisons are augmented with the broad comparisons
using (2), the odds for clonality are 5.5 X 106 to 1, overwhelmingly favoring the common
clonal origin of these two tumors.

Our second example from Section 2 comes from a study of 19 patients with double
primary melanomas that were assembled to examine the possible relationship of second
primary melanomas with their initial primaries. These samples were examined for LOH
at a set of candidate markers, and the results seem to confirm generally that most if not
all of the tumors are independent (Orlow et al. 2008). However, for two of the 19
patients, the comparison of the LOH profiles was marginally statistically significant, and
for one of these we had sufficient tumor tissue to obtain ACGH on both tumors (note that
most primary cutaneous melanomas are too small for CGH analysis using current
technology). This case is displayed in Figure 3. The likelihood ratio from the broad
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correlation of the gains and losses favors independence with odds of 31 to 1. There are
3 concordant mutations amenable to a comparison of the specific changes with the
following results: 2p, 15 to 1 favoring of clonality; 17q, 5 to 1 favoring independence;
22q, 1.3 to 1 favoring independence. Thus the aggregate likelihood ratio is 13 to 1 in
favor of independence.

These previous examples lead us to likelihood ratios that ideally represent the strengths
of evidence favoring each of the hypotheses/diagnoses for the patient, H I versus H C .
For the first patient we arrived at odds for H C of 5.5 x 106 to 1. But do these seemingly
overwhelming odds really supply the certainty of the diagnosis of H C that the numbers
imply? All of the examples we present involve clinical scenarios where the “correct”
diagnosis is uncertain. That is, clinical and pathological data do not provide us with a
“gold standard” reference diagnosis, and indeed a goal of research into the use of
molecular techniques such as ACGH in this setting is to provide a more accurate
standard. However, when we have at our disposal a more complete dataset of patients
from the clinical scenario under investigation, we can create a plausible reference
distribution for our diagnostic statistics under H I by comparing pairs of tumors from
different patients, tumors which necessarily arose independently. In the following more
comprehensive analyses we use this strategy to add further insights into the properties
of our method.

First we examine the 22 patients from the study by Bollet et al. (2008). Clinical details
are provided in Table 1, along with the diagnostic classifications based on our analyses.
The goal for each patient is to determine if a second ipsilateral breast cancer is a new
primary or a recurrence of the initial primary cancer. Clinical diagnoses were determined
based on the congruence of the histology and location of the tumors. Second tumors
were classified as recurrences (i.e. clonal, C) if they had the same histologic subtype, a
similar or increased growth rate, a similar or loss of dependence on either estradiol or
progesterone, and a similar or increased differentiation compared with the initial primary
(see Bollet et al. 2008). On this basis, 9 of the 22 patients were classified as
independent primaries (I), and the remaining 13 were classified as clonal (C). The final 3
columns of Table 1 show the broad likelihood ratio calculations using (1), the likelihood
ratio augmented with results from specific within-chromosome comparisons using (3),
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and the diagnoses based on the latter statistics. For this dataset we classified cases as
independent if ln(LR2) < -0.5, equivocal if -0.5 < ln(LR2) < 6, and clonal if ln(LR2) > 6, for
reasons further described below. Our classifications are mostly in agreement with the
clinical classifications, with the notable exception of case #22. For this case, considered
clinically to represent two independent tumors, the broad correlation (LR1) modestly
favors the clonal hypothesis but there are individual mutations that point strongly to
clonality on 8p (80 to 1) and 11q (36 to 1), leading to a final likelihood ratio in favor of
clonality of 3.6 x 103 to 1. These individual mutations are plotted on the top two panels of
Figure 4. Interestingly, this case also highlights some of the practical difficulties we face
in accounting for the evidence in a fully algorithmic way. Although our method identifies
most potentially clonal mutations, it will occasionally miss some possible candidates due
to arbitrary features of the selection algorithm. For example, we only compare mutations
that are both designated as either gains or losses. In the lower two panels of Figure 4 we
see highly plausible clonal mutations that were missed. For 6p, the short segment in the
first tumor (top panel) is considered a loss, while for the second tumor the long segment
is considered a gain. This is because we make the classification of gain versus loss on
the basis of the distance from the normal copy number, itself estimated from the average
of all the markers in the array. Yet, this clearly looks like a highly plausible clonal event.
A similar pattern emerges in 13q. Thus the evidence for clonality in this patient may be
substantially stronger than is represented by the formal analysis.

This patient represents an example of a case in which the molecular evidence seems to
clearly contradict the diagnosis based on standard clinical criteria. However, the data are
not always so clear-cut, and it is also much harder to be convinced that two tumors are
independent, since independence is characterized (visually) merely by the absence of
strikingly clonal features such as the allelic changes highlighted in Figure 4. One way to
judge the credibility of our calculated likelihood ratios is to create a benchmark reference
distribution for independent comparisons by conducting analyses on all comparisons
formed by pairing tumors from different patients, a strategy that has also been used by
Bollet et al. and others. Our two sets of 22 tumors provide 22X21=462 such independent
pairings (where each pair contains one 1st primary and one 2nd primary) and the
likelihood ratios (using (3)) for these pairings are displayed in Figure 5 in the black
histogram. Superimposed in red with cross-hatching is a histogram of the results from
the 22 actual within-patient comparisons (from Table 1). The results show that a
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likelihood ratio of 3.8 to 1 (ln(LR2)=1.3) corresponds to the upper 99th percentile of the
likelihood ratio distribution for independent tumors, and so values considerably in excess
of this are unlikely by chance. In this and subsequent analyses we define the region from
the 95th percentile of the reference distribution to the maximum value recorded as an
“equivocal” diagnostic region. It can be seen from Figure 5 that for this dataset the
equivocal region spans ln(LR2) values between -0.9 and 5. Consequently the 13
patients with likelihood ratios in excess of this region (including case #22) would appear
to be definitively clonal. For the 4 patients with log LR2 values below -0.9 the evidence
strongly favors independence. Five patients fall into the “equivocal” zone, with odds
favoring clonality of 1.9 to 1 (case #2), 9.4 to 1 (case #6), 5.5 to 1 (case #12), 4.1 to 1
(case #16), and 1 to 1 (case #20). These results give confidence that with good quality
data the method has the potential to provide definitive classifications for the majority of
patients.

We have applied the same series of analyses to another published example, this time a
comparison of LCIS and ILC breast tumors from each of 24 patients (Hwang et al. 2004).
The purpose of this study was to examine the general hypothesis that LCIS is a
precursor lesion to invasive breast cancer (ILC), and so the authors were interested in
the frequency with which clonal relatedness could be identified or proved. The results
are characterized in the two histograms (Figure 6), calculated in a similar way to Figure
5 above. That is, all possible pairings of LCIS and ILC tumors from different patients
were analyzed and the resulting distribution of likelihood ratios is displayed in black. This
distribution has slightly greater spread than for the Bollet et al. data. In fact, the
equivocal region stretches from a log LR2 value of 0.3 to a value of 8. The juxtaposition
of the 24 actual within-patient comparisons in red with the reference histogram again
produces a group of patients with very strong evidence for clonal relatedness (8 of the
24 patients). The remaining cases are spread through the “equivocal” (5 patients) and
“independent” (11 patients) regions.

We performed a similar analysis on our dataset of 21 tumors from 9 patients with
multiple head and neck cancers, from which our illustrative patient in Figures 1 and 2
was drawn. Eight of the tumor pairings were considered clinically and pathologically to
represent tumor recurrences. Only two of these pairings produce strongly clonal
patterns. These are the two extreme observations on the right of Figure 7 in red. One
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case, considered clinically to be an independent primary, has odds in favor of clonality of
78 to 1. However, this falls in the equivocal range of the independent reference
distribution for this dataset, which spans likelihood ratios that nominally favor the clonal
hypothesis by large factors, with ln(LR2) values ranging from 4 to 12.

It is noticeable from Figure 7 that the reference distribution of likelihood ratios from
independent pairings is much broader than for the other two datasets in Figures 5 and 6
and includes likelihood ratios whose nominal values strongly favor the clonal hypothesis.
This appears to reflect the fact that the datasets differ with respect to the clarity with
which allelic changes are detected. Defining the signal strength to be the 90th percentile
of the absolute values of the detected segment means divided by the standard deviation
of the residuals, reflecting how separated the larger segment means are from the rest of
the array values, we find that the mean signal strengths are 4.2 for the Bollet et al. data,
3.6 for the Hwang et al. data, and 2.4 for the head and neck dataset. High signal
strength would appear to translate into a tighter reference distribution, and to clearer
separation of tumor pairs into clusters representing independent pairs and clonal pairs.
Signal strength also appears to affect the normative values of the likelihood ratios, which
should generally be less than 1 for independent tumors. The upper 95th percentile of the
reference distribution for independent pairings is 0.4 to 1 for the Bollet et al. data, 1.3 to
1 for the Hwang et al. data, but it is 59 to 1 for the head and neck cancer dataset. While
the arrays were performed on fresh frozen tissue in the studiy by Bollet et al.,, the head
and neck study used formalin fixed paraffin embedded tissue, and it is well known that
this source of tissue produces ACGH arrays of much poorer quality.

Finally, we have evaluated the sensitivity of our analyses to the arbitrary choice of

c = 0.5 as our parameter representing the relative frequency of clonal mutations in tumor
pairs that are genuinely clonal. We repeated all of our analyses with c = 0.2 and with

c = 0.8. For the Bollet et al. dataset all three analyses produce consistent diagnoses for
18 of the 22 patients (82%). [Here we define consistency to represent likelihood ratios
that are consistently greater than 1 or consistently less than 1.] For all but one of the
inconsistent cases the likelihood ratio was in the equivocal range for the analyses with

c = 0.5 shown in Figure 5. For the Hwang et al. data 19 of the 24 patients (79%) were
diagnosed consistently. Three of the 5 inconsistent cases were in the equivocal range
for c=0.5. For the head and neck cancer dataset only 2 of the 15 comparisons had
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strong evidence for clonality at c = 0.5 , and this pattern re-emerged for analyses at

c = 0.2 and c = 0.8 . These results suggest that when the analysis provides very strong
evidence for either H C or H I we can be confident of the diagnosis despite the arbitrary
choice of c. Conversely, log likelihood ratios in the equivocal range must be viewed with
caution. The results also support the use of a “signal strength” measure of the clarity of
the allelic changes observed, as suggested in the previous paragraph, to characterize
the quality of the array data and the consequent conclusiveness of the resulting
diagnoses.

6. Discussion

Cancer pathology is in a period of fast evolution at present, stimulated by the knowledge
gained from the sequencing of the human genome, and from related developments
(Triche 2006). Historically, pathologists have diagnosed cancer on the basis of histologic
and cytologic features observed by macro- and micro-scopic examination, in recent
years complemented by various laboratory tests. They make differential diagnoses of
metastases from second independent primaries on the basis of the comparability of
these pathologic features, along with relevant clinical information and common sense
rules regarding this information, such as the expectation that a metastasis would be
unlikely to have cells that have better differentiation, or an in situ component. However,
ultimately, it is generally accepted that the crucial features of a cancer that determine its
behavior and ancestry are the somatic mutations that have accumulated in the tumor
cells. Thus, examination of these mutational patterns holds the definitive key to the
accurate differential diagnosis of a metastasis versus a second independent primary
cancer.

Our goal in this work has been to develop a formal statistical procedure to make the
differential diagnosis of metastases from second independent primaries on the basis of
somatic genetic fingerprints obtained from ACGH data. However, this is difficult for many
reasons. In this article we have focussed on the statistical challenges. The first, and
possibly the most difficult step, is to organize the voluminous data into a conceptual
framework that facilitates formal statistical analysis. Because of the richness and
complexity of the data, this process is necessarily somewhat ad hoc, following a growing
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tradition in statistical genomics (Speed 2008). After considering numerous options for
summarizing the data, our belief is that the pivotal information for establishing the clonal
origin of pairs of tumors lies in the precise comparison of the locations of specific allelic
gains and losses that are potentially clonal events. Our strategy thus inevitably involves
multiple stages. We must use segmentation methods to first identify the allelic gains and
losses, and then we must use the new methods presented in this article to assess the
closeness of their estimated locations. These comparisons are building blocks of
information that are then combined with the gross correlation patterns of the losses and
gains across the genome to determine an overall diagnosis for the patient. In our limited
efforts to date to validate this strategy we observe that the method has good statistical
properties in an ideal setting in which there is at most a single allelic loss or gain in each
chromosome arm, and where the random errors in the marker values in the arrays are
normally distributed. The data analyses of our various examples using this methodology
suggest that the method can provide conclusive diagnoses for individual patients where
the DNA is of high quality and the clonality signals are strong.

A difficult feature of the problem is the fact that the two hypotheses that we are trying to
distinguish are structured very differently. Under the independence hypothesis, H I , the
somatic mutational patterns are presumed to have arisen independently. However, we
know that different genetic loci experience mutations with very different frequencies in
cancers, and so the method requires knowledge of these “marginal” mutation
probabilities to effectively filter out the induced correlation that will necessarily occur in
the mutational profiles of biologically independent tumors. Our knowledge at present of
these marginal probabilities, which are different for different cancer types, is limited, and
we chose to estimate them from the relatively small data sets at our disposal. Under the
clonal hypothesis, H C , the tumors are linked by allelic gains or losses that occurred in
the original “clonal” cell that led to the cancers, and are thus identical. Therefore H C is
characterized by tumors that share some (at least one) clonal mutations, but these
tumors may, and usually do, harbor numerous other non-clonal mutations.
Consequently, we need a method that appropriately weighs the negative evidence of the
presence of clearly non-clonal mutations against the positive evidence of closely
matching mutations. We have approached the problem by constructing a likelihood in
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which the relative frequency of clonal mutations in tumors that are clonal is assumed
known ( c ), but in practice we have very limited knowledge of this parameter.

Because of the preceding features, we have leaned heavily in interpreting our analyses
on the use of a “null” distribution of our likelihood ratio statistic, created by comparing
tumors from different patients, tumors which are necessarily independent. Thus, despite
the fact that the purpose of our analysis is differential classification of patients into H C
and H I our analysis ultimately has a significance testing flavor in which we rely on the
null distribution of the statistic under H I to help define the appropriate diagnostic
classifications. We note that a simple strategy for analyzing the data would be to
formulate the problem as a significance test, with the diagnosis of independence as the
null hypothesis, denoted H I . The broad correlation of gains and losses could then be
viewed as a set of independent, non-identically distributed multinomials with one
outcome for each multinomial. Dale (1986) has proposed tests for independent nonidentically distributed multinomials with sparse data, and has studied their properties. In
our notation her test statistic would be

∑∑∑ (r
i

j

jki

−q jki ) 2 / q jki for j = g , l , n and

k

k = g , l , n , where i represents the chromosome arm, and where qijk = p ji p ki . However,
we examined this test in our context where each outcome r... takes the value 1 or 0. We
found that it does not appear to have good small sample properties, and so we did not
pursue this approach further. Formulation of the problem as a significance test of H I
would have followed the strategy we have used previously for the comparison of the
mutational profiles at candidate markers (Begg et al. 2007, Ostrovnaya et al. 2008).

Application of the method to our various examples demonstrates clearly that it has the
potential to convincingly establish the clinico-pathological diagnosis, and to change it in
some patients. However, there are many limitations, and much additional research is
needed to refine it and to better understand its statistical properties. The key areas for
further investigation are as follows. First, since we seek a “better” diagnosis than the
current standard, there is no gold standard benchmark against which to evaluate the
classifications of the new method. Ultimately, clinical follow-up studies of patients may
help to determine the gold standard, in that the clinical courses of patients with

24
Hosted by The Berkeley Electronic Press

metastases will generally be much worse than those of patients with new primaries. The
absence of a gold standard diagnosis also inhibits our ability to calibrate the magnitudes
of the likelihood ratios produced by the method. Second, the method requires that an
initial segmentation analysis be performed to identify the allelic gains and losses. This is
a statistical analysis in and of itself and it is influenced strongly by both the segmentation
method used and by the parameters of this analysis, namely the significance level for
detecting an allelic change, and the MAD criterion for ensuring that the signal detected is
sufficiently strong. Third, our method requires specification of marginal mutation rates in
each chromosome arm, and a specification of the parameter c that characterizes the
strength of the clonality signal. Although we need further research to understand the
sensitivity of the method to errors in the specification of these parameters, our sensitivity
analyses provide us with some confidence that diagnoses with high likelihood ratios are
insensitive to the choice of c . Fourth, we have restricted the entire testing strategy to the
assumption that each chromosome arm possesses at most one allelic gain or loss. In
practice, sometimes multiple changes may be observed within a single chromosome
arm. If these more complex patterns match closely on the two tumors the evidence
favoring clonality can be greatly enhanced. Indeed we see such a pattern in Figure 8.
This is from chromosome 5q on patient #13 in the Bollet et al. data, a patient with strong
overall evidence for clonality. The segmentation for this plot is not restricted to the first
detected allelic change, as in our previous analyses. We restricted our method to onestep changes for analytical simplicity, but the method could benefit from further
refinement to accommodate complex changes of this nature which would seem to
provide very strong evidence for clonal relatedness. Finally, we have focussed on the
statistical issues, but in practice there are numerous practical aspects of molecular
testing that can greatly influence the data and the resulting analyses. To accomplish
ACGH testing tumor cells must be isolated for analysis. The tumor cells may be
substantially contaminated with normal stromal or interstitial cells, and this can radically
reduce the detectable signal in the allelic changes. As we have seen in our examples,
the “quality” of the array data can also be affected by whether the tumor samples are
fresh frozen or obtained from formalin fixed paraffin-embedded archival material.

The “quality” of the array data is reflected in the clarity of the signals that identify allelic
changes. In poor quality data it is both harder to detect the changes, and also the
endpoints of the changes are estimated with much greater variability. Our analytic
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strategy depends on several “tuning” parameters, including the significance level of the
segmentation algorithm, the MAD criterion used to try to eliminate artifactual signals, and
the choice of c to reflect the clonality signal. It also depends on further arbitrary choices,
such as how to classify changes as gains versus losses, as indicated in our discussion
of Figure 4, and on the extent to which we elected to reduce the total number of markers
by averaging adjacent markers. We need further research to determine how to select
these parameters to optimize the method, recognizing that the choices may be
dependent at the outset on the overall degree of noise in the data. We view this entire
methodology as a suggested framework for the task of differential diagnosis of
metastases and second primaries, and recognize that much additional research is
needed to refine the methodological details.
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Pt #
1
2
3
4
5
6
10
11
12
13
14
15
16
18
19
20
21
22
23
24
25
26

Table 1
Clinical Data and Results for Diagnoses of Ipsilateral Breast Cancer (Bollet et al. 2008)
Histology1
ACGH Results
Time
Clinical
st
2
3
1
2nd
LR1
LR2
Diagnosis
Diagnosis4
Interval
Quadrant
Ductal
Ductal
6.5
Same
I
4.3 x 10-4 5.0 x 10-4
I
Ductal
Lobular
5.3
Same
I
1.9
1.9
E
Ductal
Ductal
3.1
Same
C
1.1 x 104
2.0 x 105
C
Lobular
Lobular
3.5
Same
C
7.1 x 101
6.6 x 104
C
6
26
Ductal
Ductal
2.0
Same
C
1.1 x 10
3.3 x 10
C
Lobular
Lobular
3.1
Same
C
9.4
9.4
E
-2
-2
Lobular
Ductal
5.0
Different
I
2.6 x 10
2.6 x 10
I
Lobular
Ductal
6.3
Same
I
1.5 x 10-4 1.5 x 10-4
I
Lobular
Lobular
2.9
Different
I
5.5
5.5
E
Ductal
Ductal
4.6
Same
C
1.4 x 103 1.9 x 1016
C
Lobular
Lobular
2.5
Same
C
3.7 x 103
1.2 x 108
C
2
6
Ductal
Ductal
3.3
Same
C
3.9 x 10
2.7 x 10
C
Ductal
Ductal
3.8
Same
I
2.5 x 101
4.1
E
-3
-4
Ductal
Ductal
2.2
Same
I
8.7 x 10
6.3 x 10
I
Ductal
Ductal
3.0
Same
C
2.8 x 10-1
1.8 x 107
C
Ductal
Ductal
1.4
Different
I
2.2
9.9 x 10-1
E
3
27
Ductal
Ductal
4.2
Same
C
4.8 x 10
1.3 x 10
C
Ductal
Micro-Pap
3.5
Same
I
1.3
3.6 x 103
C
2
13
Ductal
Ductal
0.8
Same
C
3.6 x 10
5.5 x 10
C
Ductal
Ductal
1.0
Same
C
5.7 x 103
1.8 x 109
C
5
16
Ductal
Ductal
2.2
Same
C
3.5 x 10
2.3 x 10
C
Ductal
Ductal
1.8
Same
C
1.8 x 104 7.5 x 1013
C

1. It is presumed generally that tumors must have the same histology to be clonally
related.
2. Time interval between tumor diagnoses in years: the longer the interval, the less
likely it is that the second tumor is a metastasis.
3. A closer anatomical relationship (same quadrant) is believed to increase the
probability of clonal relatedness.
4. I – Independent Primary; C – Clonal (metastasis); E – Equivocal (diagnosis
uncertain).
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Figure 1. Whole genome segmentation of tumors from the patient with cancer of the
mouth described in Sections 2 and 5. The red (blue) lines represent allelic gains (losses)
as determined by the segmentation algorithm.
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Figure 2. Detailed view of chromosome 10q segmentation of the patient with cancer of
the mouth described in Sections 2 and 5.
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Figure 3. Whole genome segmentation of tumors from the patient with two melanomas
described in Sections 2 and 5. The red (blue) lines represent allelic gains (losses) as
determined by the segmentation algorithm.
.
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Figure 4. Clonal Mutations from Patient #22 from Bollet et al. (2008)
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Figure 5. Likelihood ratios for patients in Bollet et al. data (blue) superimposed on
reference histogram from independent tumor pairings from different patients (black).
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Figure 6. Likelihood ratios for patients in Hwang et al. data (blue) superimposed on
reference histogram from independent tumor pairings from different patients (black).
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Figure 7. Likelihood ratios for patients in head and neck cancer dataset (blue)
superimposed on reference histogram from independent tumor pairings from different
patients (black).
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Figure 8. Example of a closely matching complex change, from 5q on patient #13 in
Bollet et al. (2008).
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